Manitoba

NO LONGER ACTIVE location in Manitoba:

• Winnipeg – CancerCare Manitoba (Mohamed Akra, MD: 204-787-4156 )

ID Number: NCT01924819

Links:

• ClinicalTrials.gov
• Canadian Cancer Trials

Description: This study is trying to understand the best way to treat patients with resectable gastric cancer before their surgery. The researchers want to see if chemotherapy with radiation (chemoradiotherapy) is more helpful than just chemotherapy before surgery.  There will be two groups compared in this experiment:

• Group A – will have chemotherapy + chemoradiotherapy before surgery.
• Group B – will have only chemotherapy before surgery.

All patients in this study will be having a gastrectomy and a D1 lymphadenectomy. Then, all patients will have chemotherapy after surgery. The researchers will be looking at overall survival in the two groups over time. The estimated end date for the study is December, 2020.

Intervention:

• Group A: chemotherapy (epirubicin, cisplatin, fluorouracil) with radiation before surgery, and chemotherapy after surgery
• Group B: chemotherapy (epirubicin, cisplatin, fluorouracil) before surgery and after surgery

Can I consider participating?

• Yes: patients who have stage 1B gastric or gastroesophageal tumor which is considered resectable by a surgeon.
• No: people who have had chemotherapy or radiotherapy before, advanced gastric tumors, metastatic gastric cancer

Recruiting location in Manitoba:

• Winnipeg – CancerCare Manitoba Health Sciences Centre (Dr. Gordon Buduhan: 284-707-3109)

ID Number: NCT02935634

Links:

• Clinical Trials.gov
• Canadian Cancer Trials

Description: This is a Phase III pilot trial. The participants in this study will be patients with Gastroesophageal Junction adenocarcinoma. The researchers want to know if perioperative chemotherapy or preoperative chemoradiotherapy is more helpful. This is a pilot study, which means that it is quite small and the researchers are trying to figure out if it is feasible to conduct a larger trial to answer their question with more data. They will compare the survival of two groups to try and find a better treatment for Gastroesophageal Junction cancer:

• Group 1: the perioperative chemotherapy group will receive 1 of 2 possible chemotherapy routines: epirubicin/cisplatin/fluorouracil (ECF) or fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT). The chemotherapy is given before and after surgery.
• Group 2: the preoperative group will receive chemotherapy and radiation therapy before surgery only. The drugs they will receive are carboplatin and paclitaxel.

Intervention:

• Carboplatin and paclitaxel work to stop cancer cells from dividing. In this trial, they are given along with radiation therapy to treat the cancer.
• The ECF and FLOT chemotherapy routines both work to try and stop cancer cells from dividing properly. Both are already prescribed commonly in gastric/gastroesophageal cancer treatment.

Can I consider participating?

• YES: tumor of the esophagus or gastroesophageal junction which does not extend too far into the stomach itself (no more than 2 cm), aged 18-75, tumor is less than 8 cm in length and 5 cm in diameter
• NO: have already tried chemotherapy or radiation therapy for esophageal/gastroesophageal cancer, had a malignant cancer within the last 5 years

NO LONGER Recruiting – active locations in Manitoba:

• Winnipeg – CancerCare Manitoba (Danielle Desautels, 204-787-2128)

ID Number: NCT03797326

Links:

• Clinical Trials.gov
• Canadian Cancer Trials

Description:This study is looking at the safety and effectiveness of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/Mk-7902).

Group A: Pembrolizumab and lenvatinib

Intervention: Pembrolizumab is an immunotherapy drug that will help immune system cells to attack and get rid of cancer cells. Lenvatinib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.

Can I consider participating?

• YES:  patients who have a metastatic and/or unresectable solid tumor that is uncurable, has received 2 prior lines of therapy
• NO: patients who have gastrointestinal condition, active infection or autoimmune disease